Charles River Laboratories International, Inc. CRL
292.84
(1.60)
(0.54%)
as of 25 Sep
- Market cap
- $14.1B
- P/E
- 0.0×
Follow CRL
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Charles River Laboratories International, Inc. (CRL) EBITDA
Charles River Laboratories International, Inc.'s EBITDA for fiscal 2025 was $593.5M, down 26.2% from $804.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was $553.0M. Over the past ten years it has ranged from $301.3M (fiscal 2015) to $954.8M (fiscal 2022); the current reading is higher than 55% of that period. EBITDA has fallen for 3 consecutive fiscal years. Charles River Laboratories International, Inc. ranks 15th of 52 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Annual
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $593.5M | (26.19%) |
| FY2024 | $804.1M | (13.67%) |
| FY2023 | $931.4M | (2.46%) |
| FY2022 | $954.8M | 11.63% |
| FY2021 | $855.4M | 28.12% |
| FY2020 | $667.7M | 21.56% |
| FY2019 | $549.2M | 11.37% |
| FY2018 | $493.2M | 17.58% |
| FY2017 | $419.4M | 15.16% |
| FY2016 | $364.2M | 20.87% |
Quarterly
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $187.2M | 0.07% |
| Mar 2026 | $187.0M | — |
| Dec 2025 | −$40.2M | — |
| Sep 2025 | $219.0M | (0.31%) |
| 42 more quarters | Free account |
Against its own ten years
Low $301.3M
High $954.8M
Ten-year median
$593.5M
Current reading's percentile
55
EBITDA against peers
| Company | EBITDA |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $2.2B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| RVTY Revvity Inc. compare | $775.8M |
| ICLR ICON PLC compare | $666.9M |
| QGEN QIAGEN N.V. compare | $651.0M |
| MEDP Medpace Holdings, Inc. compare | $611.2M |
| CRL Charles River Laboratories International, Inc. | $553.0M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| GH Guardant Health, Inc. compare | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CRL
- Revenue
- Net income
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement